

Case Docket No. MEWB25.001APC

Date: August 16, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Lane, David Philip

Appl. No.

09/403,440

Filed

January 19, 2000

For

MATERIALS AND

METHODS RELATING TO

INHIBITING THE

INTERACTION OF p53

AND MDM2

Examiner

Davis, M.

Group Art Unit:

1642

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

> August 16, 2001 (Date)

A LE ALLE

RECEIVED

AUG 2 2 2001

TECH CENTER 1600/2900

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) SEQUENCE SUBMISSION STATEMENT.
- (X) AMENDMENT DIRECTING ENTRY OF "SEQUENCE LISTING" INTO THE SPECIFICATION.
- (X) SUBSTITUTE SEQUENCE LISTING IN 4 PAGES AND DISKETTE CONTAINING SUBSTITUTE SEQUENCE LISTING IN ELECTRONIC FORM.
- (X) COPY OF NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410. A duplicate copy of this sheet is enclosed.
- (X) Return prepaid postcard.

Adeel S. Akhtar

Registration No. 41,394

Attorney of Record

EWB25.001 APC



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FILING DATE.	FIRST NAMED INVENTOR	<i>i</i> .	ATTORNEY, DOCKET NO.

<u>_0</u>20995

APPLICATION NO.

FINORBE MARTENS OF SON & REAP IT

STATEFMEN FLOOR

NEWFORT BRACH LA WASSO

MINT 1 / 07 1 8

O TIPE

MIN 2 0 200 PO

EXAMINER

ART UNIT PAPER NUMBER

(17/16/61 **DATE MAILED:**

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

BY: TEN VERIFIED BY:
ACTION SOME DUE
DUE DATE ALG. VO DO

JUL 2 0 2001

FINAL DEADLINE: Jan. 1612002

ATTORNEY CERTIFICATION OF DUE DATE AND FINAL DEADLINE

SERVE SERVE

RECEIVEL SAN FRANCISC (1 JUL 2 3 250)





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	A	ATTORNEY DOCKET NO.	
09/403440	_ *				
		1	EXAMINER		
			MINH-TAM DAVIS		
			ART UNIT	PAPER NUMBER	
			1642	//	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

DATE MAILED:

The communication filed on is not fully responsive to the communication mailed for the reason(s) set forth on the attached Notice to Comply With the Sequence Rules or CRF Diskette Problem Report.

Since the response appears to be <u>bona fide</u>, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE** (1) **MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner **MINH-TAM DAVIS**, Art Unit **1642**, whose telephone number is **703-305-2008**

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

ANTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, 20231

SERIAL NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO.

EXAMINER

ART UNIT PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN ONE EXTENDIBLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to whose telephone number is (703) 30

Application No. 09/4039760
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES AND 2 0 2001
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR (89) 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). 7. Other:
Applicant must provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing" An initial or substitute paper copy of the "Sequence Listing", as well as an
amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
For questions regarding compliance with these requirements, please contact
For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400
Please return a copy of this notice With your response.